Clinical Trials Sponsored by Eisai GmbH

Total 4063 results

Eisai GmbH

Completed

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Seizures

Germany
Eisai GmbH

Completed

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE)

Locally Advanced or Metastatic Breast Cancer

Germany
Eisai GmbH

Completed

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

Focal Epilepsy

Germany
Eisai GmbH

Terminated

Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Epilepsy

Germany
Institut fuer Frauengesundheit
Eisai GmbH

Recruiting

Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)

Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, Breast

Germany
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
Eisai Limited

Not yet recruiting

A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology

Alzheimer's Disease

United States
Eisai Limited

Completed

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Ovarian Cancer | Triple Negative Breast Cancer | Malignant Solid Tumour | Advanced Melanoma | B-cell Malignancy, Low-grade

United Kingdom
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
Eisai Limited

Suspended

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

Healthy Volunteers

United Kingdom
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Eisai Inc.
Eisai Limited

Completed

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Russian Federation, Italy, Belgium, Canada, South Africa, France, United States, Switzerland, Argentina, Australia, Austria, Brazil, Croatia, Czechia, Hungary, Poland, Spain
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Eisai Limited

Completed

Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain. (PRIME)

Pain Management | Severe Chronic Pain
Eisai Limited

Completed

A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)

Partial Seizures

Italy
Eisai Limited

Terminated

Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

Parkinson's Disease

France
Eisai Limited

Completed

Open Label, Zonegran (Zonisamide) In Partial Onset Seizures

Epilepsy

United Kingdom, France, Germany, Italy, Austria, Denmark, Norway
Eisai Limited

Completed

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Cognitive Impairment

United States, Spain, Australia
Eisai Limited

Completed

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Poland, France, Spain, Germany, Hungary, Italy, Estonia, South Africa, Belgium, United Kingdom, Portugal, Austria, Czech Republic, Israel, Lithuania, Serbia, Sweden
Eisai Limited

Completed

Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate

Epilepsy

Finland, Austria
Eisai Inc.
Eisai Limited

Completed

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Breast Cancer

United States, Canada
Eisai Limited

Terminated

An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine

Metastatic Breast Cancer

Russian Federation, United Kingdom, Germany, Italy, Spain
Eisai Limited

Completed

An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects

Spasmodic Torticollis

Japan
Eisai Inc.
Eisai Limited

Completed

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Eisai Limited

Completed

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Alzheimer Disease

Japan
Eisai Limited

Suspended

A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours

Cancer

Netherlands, Spain
Eisai Co., Ltd.
Eisai Limited

Completed

Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

Epilepsy

Latvia
Eisai Limited

Completed

A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Eisai Limited

Completed

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Eisai Limited

Completed

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

Alzheimer's Type Dementia

China
Eisai Limited

Completed

Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry

Breast Cancer

United Kingdom, Denmark, Ireland
Eisai Limited

Terminated

Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy

Epilepsy

Australia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
Eisai Limited

Completed

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

Parkinson's Disease

Czech Republic, France, Germany, Italy, Serbia, Spain
Eisai Limited

Terminated

Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

France
Eisai Limited

Completed

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

Colorectal Cancer (CRC)

Netherlands, France, Germany
Eisai Limited

Completed

Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

Cancer

Netherlands
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Eisai Limited

Completed

A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease

Lesion

Japan
Eisai Limited

Completed

A Comparative Study of KES524 in Patients With Obesity Disease

Obesity

Japan
Eisai Limited

Terminated

A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
VisionHealth GmbH
Thoraxklinik-Heidelberg gGmbH

Recruiting

Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.

Asthma

Germany
Eisai Limited

Completed

Extended Treatment in Metastatic Breast Cancer With Eribulin (EXTER)

Breast Cancer

Spain
Eisai Inc.
Eisai Limited

Completed

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Attention Impairment

United States, Netherlands, France, Spain, United Kingdom, Germany, Argentina, Canada, Australia, Chile
Eisai Inc.
Eisai Limited

Completed

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Eisai Limited

Completed

A Confirmation Study of Eribulin in Combination With Capecitabine

Metastatic Breast Cancer

United Kingdom, Bulgaria, Russian Federation
Eisai Limited

Completed

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Partial Seizures
Eisai Limited

Completed

The Effect of Vitamin K2 on Bone Turnover

Osteoporosis

Japan
Eisai Limited

Completed

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Lennox-Gastaut Syndrome

Japan
Eisai Limited

Completed

To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

Tumor

Netherlands
Eisai Limited

Terminated

Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures

Epilepsy

Australia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine

3

Subscribe